project id: TCGA-CESC; case submitter id: TCGA-EK-A3GM; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.87; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 2.0; rna integrity number: 9.0; age at index: 65; days to birth: -23879; ethnicity: hispanic or latino; gender: female; race: white; vital status: Alive; year of birth: 1941; age at diagnosis: 23879; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 0.0; figo stage: Stage IIA; icd 10 code: C53.9; last known disease status: not reported; morphology: 8384/3; primary diagnosis: Adenocarcinoma, endocervical type; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Cervix uteri; synchronous malignancy: No; tissue or organ of origin: Cervix uteri; tumor grade: Not Reported; year of diagnosis: 2006; treatment or therapy: not reported; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 2122; initial weight: 120.0; oct embedded: false; preservation method: Unknown; sample id: a4b92b76-ff87-475e-924b-840f652fc019; sample submitter id: TCGA-EK-A3GM-01A; portion id: cc098412-5b8d-4cd4-8f08-f06502e4cc67; portion submitter id: TCGA-EK-A3GM-01A-11; slide id: e9da4ebc-25d6-4839-ab0a-9310d0d17c29; slide submitter id: TCGA-EK-A3GM-01A-01-TSA; percent lymphocyte infiltration: 1.0; percent monocyte infiltration: 0.0; percent necrosis: 5.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 10.0; percent tumor cells: 85.0; percent tumor nuclei: 97.0; section location: TOP;